To this end, we treated proliferative M000921 and M010817 patient-derived melanoma cells (Hoek et al, 2006) with either recombinant human TGFβ or with recombinant murine Wnt-3a, or we knocked down LATS1 and LATS2 to induce the transcriptional activity of YAP/TAZ. The gene discussed is TGFB1; the disease is melanoma.